Mounjaro (Tirzepatide) is a prescription-only, pre-filled injection pen designed to support substantial and sustainable weight loss, manufactured by Eli Lilly. Mounjaro works by targeting specific pathways in the brain to help you feel fuller for longer and reduce cravings. When used alongside a calorie-controlled diet and increased physical activity, Mounjaro has been shown to promote significant weight loss beyond what diet and exercise alone can achieve.

Who is Mounjaro for

Mounjaro is intended for adults aged 18 to 74 who meet specific criteria:

Previous weight management efforts
For those who have not achieved meaningful weight loss through supervised diet, behavior changes, and increased physical activity.
Body Mass Index (BMI) requirements *
- BMI of 30 kg/m² or higher or
- BMI of 27 kg/m² or higher with at least one weight-related health condition, such as:
  - High blood pressure (hypertension)
  - High cholesterol (dyslipidaemia)
  - Obstructive sleep apnoea
  - Type 2 diabetes

Consultation process

To access Mounjaro without a traditional prescription, you will go through the following steps:

1. Complete a health questionnaire:

Provide detailed information about your health, medical history, and previous weight management attempts.

2. Pharmacist assessment:

Our pharmacist will review your responses and may reach out via phone or video call to confirm your suitability for Mounjaro.

3. Private consultation:

All consultations are private and confidential. This gives you the opportunity to ask questions and ensure Mounjaro is the right choice for your needs.

4. All-inclusive pricing:

The price you pay includes the consultation fee, with no hidden costs.

5. Identity verification:

You'll need to provide identification during the consultation to confirm that you are the intended user. This is required only during your first order.

6. Photographic evidence request:

You’ll be asked to submit photographic evidence of your weight, height, and relevant medical history to ensure safe and accurate consultation. This is also a one-time process during your initial order.

Dosage

Mounjaro follows a gradual dosing schedule to help your body adjust and minimize potential side effects as you increase to an effective maintenance dose. Starting with the lowest dose and gradually increasing it every four weeks is advised. Please select the dosage as recommended in your personalized treatment plan. If you’re uncertain about the right dose, please contact our pharmacist at (pharmacy@medino.com) before ordering.

For individuals with a BMI over 50, we strongly recommend consulting with a doctor or specialist for a comprehensive treatment plan. Our online pharmacy is unable to provide the multidisciplinary care required for such cases; however, prescriptions through the NHS from a specialist would be free of charge.

Patient information leaflet

Ingredients

Each dose contains 2.5 mg of tirzepatide in 0.6 ml solution

Other ingredients: Sodium phosphate dibasic heptahydrate, Sodium chloride, Concentrated hydrochloric acid, and sodium hydroxide (for pH adjustment), Water for injections

Usage and Instructions

Inject 2.5mg subcutaneously once per week for 4 weeks (28 days).

Warnings

Injection site:
- It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment.
Missed dose: If you miss a dose of Mounjaro and,
- If no more than 4 days have passed since your missed dose, administer it as soon as you recall. Continue with your next injection on the regularly planned day.
- If it has been over 4 days since the missed dose, omit the missed dose. Proceed with your next injection on the regularly scheduled day.
Changing day of injection:
- The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.
Storage:
- Store in a refrigerator (2 °C – 8 °C). Do not freeze. Store in original package to protect from light.
- Mounjaro may be stored unrefrigerated for up to 21 cumulative days at a temperature not above 30 °C and then the pre-filled pen must be discarded.

Acute Pancreatitis Concerns with Tirzepatide:
- Not studied in patients with a history of pancreatitis; caution advised.
- Reported cases in patients treated with tirzepatide.
- Discontinue if pancreatitis is suspected; do not restart if confirmed.
Hypoglycemia Risk in Type 2 Diabetes:
- Increased risk when combined with insulin secretagogues or insulin.
- Dose adjustment of insulin or secretagogues may be necessary.
Severe Gastrointestinal Disease Caution:
- Use with caution in patients with severe gastrointestinal diseases, including severe gastroparesis.
Diabetic Retinopathy Caution:
- Use with caution in patients with diabetic retinopathy; appropriate monitoring is advised.
Elderly Patients:
- Very limited data for patients aged ≥85 years, for which is contraindicated.
Sodium Content:
- Contains less than 1 mmol sodium (23 mg) per dose, essentially 'sodium-free'.
Interaction with Other Medicinal Products:
- Delays gastric emptying, affecting absorption of oral medications.
- Monitor closely, especially with medications having a narrow therapeutic index.
Specific Medication Interactions:
- Oral Contraceptives: Reduction in the blood concentration observed; alternative contraceptive method (barriers) recommended for fertile women starting tirzepatide therapy.
Pregnancy and Lactation:
- Limited data on use in pregnant women; not recommended.
- Unknown if excreted in human milk; weigh benefits against risks.
- Effect on human fertility unknown; no direct harmful effects in animal studies.
Effects on Driving and Machine Use:
- Negligible influence, but precautions are advised when used with sulphonylurea or insulin to avoid hypoglycemia.

Side Effects

System Organ Class	Very Common	Common	Uncommon
Immune System Disorders	Hypersensitivity reactions	Anaphylactic reaction (1), angioedema (1)
Metabolism and Nutrition Disorders	Hypoglycaemia (1) with sulphonylurea or insulin	Hypoglycaemia (1) with metformin and SGLT2ia, decreased appetite	Hypoglycaemia (1) with metformin, weight decreased
Nervous System Disorders		Dizziness (2)
Vascular Disorders		Hypotension-related events (2)
Gastrointestinal Disorders	Nausea, diarrhoea, vomiting (2), constipation (2)	Abdominal pain, vomiting (1), dyspepsia, constipation (1), abdominal distention, eructation, flatulence, gastroesophageal reflux disease	Cholelithiasis, acute pancreatitis, Cholecystitis (2)
Skin and Subcutaneous Tissue Disorders		Hair loss (2)
General and Injection Site Conditions	Fatigue, injection site reactions (1)	Injection site pain
Investigations	Heart rate increased (1), lipase increased, amylase increased (1)	Blood calcitonin increased, amylase increased (2), heart rate increased (2)